Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 13/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 13/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11715846 | 0.80 | HTR2A (0.41) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9523728 | 0.78 | SLC6A2 (0.40) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27825135 | 0.78 | TSHR (0.39) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7147295 | 0.77 | HTR2A (0.39) | HTR2ASLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL7008386 | 0.75 | OPRM1 (0.38) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL977558 | 0.70 | HTR2A (0.47) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3458741 | 0.67 | HTR2A (0.48) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1334863 | 0.67 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL27794398 | 0.67 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL136222 | 0.67 | HTR2A (0.44) | HTR2AOPRM1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115165-B2 | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-08-25 | — | — | US | disclosed |
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2011-09-15 | — | — | US | disclosed |
| EP-2277884-A1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | DHPS, TBCA, ANTXR2 | HTR2A 4792/4885OPRM1 4740/4885SLC6A2 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.